The chronic obstructive pulmonary disease (COPD) therapy market continues to suffer from the absence of any agents that can reverse disease progression and repair lung tissue. Smoking cessation is the only way to slow or halt disease progression; therapies that can reverse pathological processes and regenerate alveolar tissue have yet to be discovered. In the absence of a truly disease-modifying therapy, inhaled bronchodilator therapies are usually prescribed, and drug development has focused on improving breathing or reducing inflammation. Although inhaled medications are primarily effective in reducing the burden of COPD by easing its symptoms, patients’ quality of life still suffers. Thus, significant unmet need remains for more-effective therapies, especially for patients with severe COPD.

QUESTIONS ANSWERED

  • What clinical and nonclinical attributes are key influencers to pulmonologists’ prescribing decisions, which have limited impact, and what are potential areas of hidden opportunity?
  • How do current therapies (e.g., Boehringer Ingelheim’s Spiriva, GlaxoSmithKline’s Advair /Seretide, AstraZeneca’s Symbicort, GSK / Innoviva’s Anoro, BI’s Stiolto / Spiolto, GSK’s Trelegy) perform on key treatment drivers and goals for COPD?
  • How do key clinical and nonclinical attributes impact pulmonologists’ preference for and likelihood to prescribe a hypothetical new COPD drug?

PRODUCT DESCRIPTION

Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 61 U.S. and 30 European pulmonologists fielded in February 2020

Key companies: GSK, Boehringer Ingelheim, AstraZeneca, Novartis

Key drugs: Spiriva, Advair / Seretide, Symbicort, Utibron / Ultibro, Anoro, Stiolto / Spiolto, Trelegy

Table of contents

  • Chronic Obstructive Pulmonary Disease - Unmet Need - Detailed, Expanded Analysis: Moderate To Severe (US/EU)
    • Executive Summary
      • Unmet Need - Severe to Very Severe COPD - Executive Summary - April 2020
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Rationale for Drug Selection
          • Products for Severe to Very Severe COPD and Rationale for Drug Selection
      • Treatment Drivers and Goals
        • Key Findings: Attribute Importance
        • Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Pulmonologists' Prescribing Decisions in Severe to Very Severe COPD
        • Importance of Efficacy Attributes to Prescribing Decisions in Severe to Very Severe COPD: United States
        • Importance of Efficacy Attributes to Prescribing Decisions in Severe to Very Severe COPD: Europe
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Severe to Very Severe COPD: United States
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Severe to Very Severe COPD: Europe
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Severe to Very Severe COPD: United States
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Severe to Very Severe COPD: Europe
        • Importance of Nonclinical Factors to Prescribing Decisions in Severe to Very Severe COPD: United States
        • Importance of Nonclinical Factors to Prescribing Decisions in Severe to Very Severe COPD: Europe
        • Key Findings: Stated vs. Derived Importance
        • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Severe to Very Severe COPD: United States
        • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Severe to Very Severe COPD: Europe
      • Product Performance Against Treatment Drivers and Goals
        • Key Findings
        • Overall Performance of Key Therapies for Severe to Very Severe COPD: United States
        • Overall Performance of Key Therapies for Severe to Very Severe COPD: Europe
        • Mean Overall Performance of Key Therapies for Severe to Very Severe COPD: United States and Europe
        • Relative Performance of Key Therapies for Severe to Very Severe COPD Across Select Efficacy Attributes: United States
        • Relative Performance of Key Therapies for Severe to Very Severe COPD Across Select Efficacy Attributes: Europe
        • Relative Performance of Key Therapies for Severe to Very Severe COPD Across Select Safety and Tolerability Attributes: United States
        • Relative Performance of Key Therapies for Severe to Very Severe COPD Across Select Safety and Tolerability Attributes: Europe
        • Relative Performance of Key Therapies for Severe to Very Severe COPD Across Select Convenience of Administration Attributes: United States
        • Relative Performance of Key Therapies for Severe to Very Severe COPD Across Select Convenience of Administration Attributes: Europe
        • Relative Performance of Key Therapies for Severe to Very Severe COPD Across Select Nonclinical Attributes: United States
        • Relative Performance of Key Therapies for Severe to Very Severe COPD Across Select Nonclinical Attributes: Europe
      • Assessment of Unmet Need
        • Key Findings: Unmet Need in Severe to Very Severe COPD
        • Surveyed Pulmonologists’ Satisfaction with the Performance of Key Therapies for Severe to Very Severe COPD on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
        • Surveyed Pulmonologists’ Satisfaction with the Performance of Key Therapies for Severe to Very Severe COPD on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
        • Surveyed Pulmonologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Severe to Very Severe COPD: United States
        • Surveyed Pulmonologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Severe to Very Severe COPD: Europe
        • Surveyed Pulmonologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Severe to Very Severe COPD: United States
        • Surveyed Pulmonologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Severe to Very Severe COPD: Europe
        • Surveyed Pulmonologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Severe to Very Severe COPD: United States
        • Surveyed Pulmonologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Severe to Very Severe COPD: Europe
        • Surveyed Pulmonologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Severe to Very Severe COPD: United States
        • Surveyed Pulmonologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Severe to Very Severe COPD: Europe
        • Key Findings: Unmet Need in Severe to Very Severe COPD and Related Indications
        • Surveyed Pulmonologists' Ascribed Level of Unmet Need in Severe to Very Severe COPD and Related Indications: United States
        • Surveyed Pulmonologists' Ascribed Level of Unmet Need in Severe to Very Severe COPD and Related Indications: Europe
      • Opportunity Analysis
        • Areas of Opportunity in the Severe to Very Severe COPD Market and Emerging Therapy Insights
          • Opportunity: Therapies That Can Lead to Greater Reduction in Exacerbation Rate
          • Opportunity: Therapies Demonstrating Greater Improvement in Lung Function Compared with Current Therapy
          • Opportunity: Therapies That Can Halt Disease Progression, Reduce Daily Symptoms, and Improve Quality of Life
      • Target Product Profiles
        • Assessing Drug Development Opportunities
        • Target Product Profile Methodology
          • Attributes and Attribute Levels
          • Attributes of Key Current and Late-Phase Emerging Therapies for COPD
        • Attribute Importance and Part-Worth Utilities
          • Severe to Very Severe COPD Target Product Profile: Attribute Importance
          • Improvement in Trough FEV1 at 52 Weeks (Placebo-Adjusted)
          • Reduction in Frequency of Exacerbations over 52 Weeks (% Reduction, Placebo-Adjusted)
          • QOL Improvement at 12 Weeks (% Patients with SGQR Score Gain of 4+, Placebo-Adjusted)
          • Improvement in Exercise Endurance at 6 Weeks (%, Placebo-Adjusted)
          • Time on Market
          • Delivery Burden (Formulation and Frequency)
          • Price per Day
        • Conjoint Analysis-Based Simulation of a Market Scenario
          • Severe to Very Severe COPD Market Simulation: Share of Preference of Target Product Profiles Included in the Market Scenario
          • Severe to Very Severe COPD Market Simulation: Likelihood to Prescribe Target Product Profiles Included in the Market Scenario
          • Severe to Very Severe COPD Market Simulation: Target Product Profiles Included in the Market Scenario
      • Appendix
        • Key Abbreviations

    Author(s): Qinghui Yu, PhD

    Qinghui Yu is a business insights analyst at Decision Resources Group. She has authored market research reports analyzing market trends in autoimmune diseases.

    Prior to joining Decision Resources Group, Dr. Yu worked as a senior analyst for a life science consulting firm, where she worked on a range of projects providing strategic growth advice to clients in life science industries. Qinghui Yu holds a Ph.D. in Neuroscience from Columbia University.


    Related Reports

    Chronic Obstructive Pulmonary Disease - Landscape & Forecast - Disease Landscape & Forecast

    The large therapeutic market for chronic obstructive pulmonary disease (COPD), a disease that is closely associated with smoking, continues to expand and is expected to grow from approximately $15...

    View Details

    Chronic Obstructive Pulmonary Disease | Disease Landscape and Forecast | G7 | 2020

    The chronic obstructive pulmonary disease (COPD) therapy market is continuing its gradual shift away from long-acting beta2 agonist/inhaled corticosteroid fixed-dose combinations (LABA/ICSFDCs) tow...

    View Details

    Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Janssen Proprietary Content

    In this project, comissioned by Janssen in December, 2018, we have packaged our published estimates on the epidemiology of CLL - drug treated population across all the countries in Latin Ameri...

    View Details